Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
Miller AR et al.
Bmc Cancer, 2025
Oncogenic Activity and Sorafenib Sensitivity of ARAF p.S214C Mutation in Lung Cancer.
Lee C et al.
Cancers, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.
Tseng YH et al.
Cell Death Discovery, 2025
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
RAF-MEK-ERK pathway in cancer evolution and treatment.
Ullah R et al.
Seminars in Cancer Biology, 2022
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Pan-cancer assessment of mutational landscape in intrinsically disordered hotspots reveals potential driver genes.
Zou H et al.
Nucleic Acids Research, 2022
Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma.
Yin XQ et al.
Frontiers in Oncology, 2022
eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants.
Thornton AM et al.
Plos Computational Biology, 2021
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston B et al.
Nature Communications, 2021
Inhibition of RAF dimers: it takes two to tango.
Cook FA et al.
Biochemical Society Transactions, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Li D et al.
Nature Medicine, 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
Revealing A-Raf functions through its interactome.
Zhang XY et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
Kanno E et al.
Experimental Cell Research, 2018
Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.
Ma P et al.
Nature Communications, 2017
High-throughput Phenotyping of Lung Cancer Somatic Mutations.
Berger AH et al.
Cancer Cell, 2016
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Casadei Gardini A et al.
Bmc Cancer, 2016
Histiocytic neoplasms in the era of personalized genomic medicine.
Durham BH et al.
Current Opinion in Hematology, 2016
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.
Desai A et al.
Cancer Biology & Medicine, 2016
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL et al.
Cancer Discovery, 2016
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.
Wang R et al.
Oncotarget, 2015
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Sereno M et al.
Anti-cancer Drugs, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG et al.
Cancer Discovery, 2015
A-Raf: A new star of the family of raf kinases.
An S et al.
Critical Reviews in Biochemistry and Molecular Biology, 2015
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
Imielinski M et al.
The Journal of Clinical Investigation, 2014